Ulobetasol
Chemical compound
- D07AC21 (WHO)
D05AX55 (WHO) (combination with tazarotene)
- (6α,11β,16β)-21-Chloro-6,9-difluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
- 98651-66-2
N
- 5311167
- 4470691
Y
- 9P6159HM7T
- D08660 Y
- ChEMBL1201360 N
- DTXSID60243759
- Interactive image
- ClCC(=O)[C@]3(O)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\C(=C/C(=O)\C=C\1)[C@@H](F)C[C@H]4[C@@H]2C[C@@H]3C)C)C
InChI
- InChI=1S/C22H27ClF2O4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1Y
- Key:LEHFPXVYPMWYQD-XHIJKXOTSA-NY
N
Y (what is this?) (verify)Ulobetasol (INN) or halobetasol (USAN) is a corticosteroid used to treat psoriasis.[1][2] It is a class I corticosteroid under the US classification and a group III corticosteroid under international classification, the most potent group of such drugs.[3][4]
Ulobetasol propionate is usually supplied as a 0.05% topical cream.[1] Ulobetasol is the strongest topical steroid available.[citation needed] It is also sold with tazarotene with 0.01% halobetasol and 0.045% tazarotene as a lotion branded as Duobrii (Bausch Health).
It is available as a generic medication.[5]
References
- ^ a b "Ultravate product monograph" (PDF). Retrieved 2021-01-04.
- ^ DrugBank DB00596 . Retrieved 2020-01-04.
- ^ Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleischer AB, Feldman SR (July 2004). "Class I topical corticosteroid use by psoriasis patients in an academic practice". The Journal of Dermatological Treatment. 15 (4): 235–8. doi:10.1080/09546630410033745. PMID 15764038. S2CID 2757493.
- ^ ATC code D07AC21 (WHO). Retrieved 2020-01-04.
- ^ "Ulobetasol international". Drugs.com. 10 August 2020. Retrieved 15 August 2020.
External links
- "Halobetasol". Drug Information Portal. U.S. National Library of Medicine.
- "Halobetasol propionate". Drug Information Portal. U.S. National Library of Medicine.
- halobetasol at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- v
- t
- e
| Natural | |
|---|---|
| Synthetic |
|
- Antagonists: Aglepristone
- Ketoconazole
- Mifepristone
- Ulipristal acetate
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Glucocorticoid receptor modulators
- Mineralocorticoids and antimineralocorticoids
- List of corticosteroids
Portal:
Medicine
 | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
